Table 2. Association of stromal cell expression of α-SMA, FSP, CD105 and CD146 with classical prognostic markers, metastatic recurrence and local relapse of 56 untreated early breast cancer patients.
| Characteristics | α-SMA | FSP | CD105 | CD146 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | High expression | p (adjusted p) * | n | Positive | p (adjusted p) * | n | High expression | p (adjusted p) * | n | Positive | p (adjusted p) * | |
| Age (years) | ||||||||||||
| < 50 | 8 | 5 (62.50) | >0.9999 | 8 | 3 (37.50) | 0.7032 | 8 | 2 (25.00) | >0.9999 | 8 | 2 (25.00) | 0.4448 |
| ≥ 50 | 41 | 26 (63.41) | (>0.9999) | 40 | 20 (50.00) | (0.9497) | 39 | 9 (23.08) | (>0.9999) | 43 | 19 (44.19) | (0.9249) |
| Tumor size (cm) | ||||||||||||
| <2 | 39 | 28 (71.79) | 0.1913 | 38 | 22 (57.89) | 0.2147 | 38 | 5 (13.16) | 0.0210 | 41 | 16 (39.02) | >0.9999 |
| ≥ 2 | 14 | 7 (50.00) | (0.8084) | 14 | 5 (35.71) | (0.8036) | 13 | 6 (46.15) | (0.2292) | 14 | 6 (42.86) | (>0.9999) |
| Histological grade | ||||||||||||
| G1/G2 | 30 | 21 (70.00) | 0.5648 | 29 | 16 (55.17) | 0.7804 | 30 | 5 (16.67) | 0.3270 | 32 | 11 (34.37) | 0.4055 |
| G3 | 23 | 14 (60.87) | (0.9134) | 23 | 11 (47.83) | (0.9736) | 21 | 6 (28.57) | (0.8399) | 23 | 11 (47.83) | (0.9319) |
| HER2/neu status | ||||||||||||
| Negative | 32 | 20 (62.50) | 0.5647 | 31 | 15 (48.39) | 0.5822 | 28 | 6 (21.43) | >0.9999 | 32 | 12 (37.50) | 0.7818 |
| Positive | 21 | 15 (71.43) | (0.9247) | 21 | 12 (57.14) | (0.8868) | 23 | 5 (21.74) | (>0.9999) | 23 | 10 (43.48) | (0.9571) |
| ER status | ||||||||||||
| Negative | 15 | 10 (66.67) | >0.9999 | 15 | 7 (46.67) | 0.7619 | 13 | 3 (23.08) | >0.9999 | 15 | 8 (53.33) | 0.2396 |
| Positive | 38 | 25 (65.79) | (>0.9999) | 37 | 20 (54.05) | (0.9597) | 38 | 8 (21.05) | (>0.9999) | 40 | 14 (35.00) | (0.8483) |
| PR status | ||||||||||||
| Negative | 14 | 8 (57.14) | 0.5147 | 14 | 6 (42.86) | 0.5364 | 12 | 2 (16.67) | 0.7158 | 14 | 8 (57.14) | 0.2059 |
| Positive | 39 | 27 (69.23) | (0.9496) | 38 | 21 (55.26) | (0.9009) | 39 | 9 (23.08) | (0.9472) | 41 | 14 (34.15) | (0.8174) |
| Regional lymph nodes | ||||||||||||
| Negative | 38 | 28 (73.68) | 0.0524 | 37 | 22 (59.46) | 0.2086 | 36 | 5 (13.89) | 0.1180 | 40 | 15 (37.50) | 0.7582 |
| Positive | 14 | 6 (42.86) | (0.4038) | 14 | 5 (35.71) | (0.8037) | 14 | 5 (35.71) | (0.6721) | 14 | 6 (42.86) | (0.9643) |
| Metastatic recurrence | ||||||||||||
| Negative | 37 | 25 (67.57) | 0.4856 | 37 | 19 (51.35) | 0.6180 | 36 | 4 (11.11) | 0.0012 | 39 | 14 (35.90) | 0.3109 |
| Positive | 11 | 6 (54.55) | (0.9495) | 11 | 4 (36.36) | (0.9096) | 11 | 7 (63.64) | (0.0224) | 11 | 6 (54.55) | (0.8485) |
| Local relapse | ||||||||||||
| Negative | 43 | 28 (65.12) | >0.9999 | 44 | 21 (47.73) | >0.9999 | 42 | 9 (21.43) | 0.5776 | 45 | 18 (40.00) | >0.9999 |
| Positive | 5 | 3 (60.00) | (>0.9999) | 4 | 2 (50.00) | (>0.9999) | 5 | 2 (40.00) | (0.8902) | 5 | 2 (40.00) | (>0.9999) |
HER2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; PR: Progesterone receptor; α-SMA: α-smooth muscle actin; FSP: Fibroblast surface protein, CD105: Endoglin; CD146: Melanoma cell adhesion molecule.
*The association between variables was performed using the Fisher Exact-test. Multiple testing adjusted p-values were computed using the Benjamini-Hochberg correction